SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies.

Manuel GrafSae Lim von StuckradAkinori UruhaJens KlotscheLydia Zorn-PaulyNadine UnterwalderThomas ButtgereitKrusche MartinChristian MeiselGerd-Rüdiger R BurmesterFalk HiepeRobert BiesenTilmann KallinichWerner StenzelUdo SchneiderThomas Rose

Published in: RMD open (2022)

SIGLEC1 is a candidate biomarker to assess type I interferon activity in IIM and proved useful for monitoring disease activity and response to treatment in juvenile and adult DM.

Keyphrases

disease activity
rheumatoid arthritis
systemic lupus erythematosus
rheumatoid arthritis patients
ankylosing spondylitis
dendritic cells
juvenile idiopathic arthritis
type diabetes
metabolic syndrome
young adults
adipose tissue
insulin resistance